Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction

被引：2

作者：

Packer, Milton ^{[1
,2
]}

Cleland, John G. F. ^{[3
]}

Bauersachs, Johann ^{[4
]}

机构：

[1] Baylor Heart & Vasc Inst, Dallas, TX USA

[2] Imperial Coll, London, England

[3] Univ Glasgow, British Heart Fdn Ctr Res Excellence, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland

[4] Hannover Med Sch, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany

来源：

EUROPEAN HEART JOURNAL | 2024年 / 45卷 / 25期

关键词：

Heart failure; SGLT2; inhibitor; Pharmacotherapy; Foundational drugs; Hospitalization; EMPAGLIFLOZIN; RISK; DAPAGLIFLOZIN; HYPERTENSION; METAANALYSIS; DIURETICS; MORTALITY; MEDICINE; BENEFITS; OUTCOMES;

D O I：

10.1093/eurheartj/ehae300

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Graphical Abstract SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction. ARNI, angiotensin receptor-neprilysin inhibitor; CV, cardiovascular; GRMT, guideline-recommended medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium-glucose cotransporter 2 inhibitor.

引用

页码：2186 / 2196

页数：11

共 50 条

[21] Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
Clemmer, John S.
Ward, Taylor J.
Lirette, Seth T.
ESC HEART FAILURE, 2023, 10 (03): : 2010 - 2018
[22] SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction
Hias, Julie
Hellemans, Laura
Walgraeve, Karolien
Tournoy, Jos
Van der Linden, Lorenz
DRUGS & AGING, 2022, 39 (03) : 185 - 190
[23] Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
De Lorenzi, Andrea Beatriz
Kaplinsky, Edgardo
Zambrano, Marx Rivera
Chaume, Laia Tomas
Rosas, Joan Monell
DRUGS IN CONTEXT, 2023, 12 : 1 - 16
[24] SGLT-2 inhibitors in the treatment of heart failure with reduced ejection fraction: a systematic review
Paffer, Pedro Toscano
Bezerra de Albuquerque Cortez, Isabelly Regina
Damasso Lisboa Costa, Marcelo Danilo
da Costa Neta, Maria Rosalia
Tavares Pedroza Monteiro, Marina Lins
Paffer, Matheus Toscano
Terra Lopes, Vitoria Maria
de Paffer Filho, Silvio Hock
AMERICAN HEART JOURNAL, 2021, 242 : 167 - 167
[25] SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
Silva-Cardoso, Jose
Andrade, Aurora
Brito, Dulce
Ferreira, Jorge
Fonseca, Candida
Peres, Marisa
Franco, Fatima
Moura, Brenda
REVISTA PORTUGUESA DE CARDIOLOGIA, 2021, 40 (09) : 687 - 693
[26] Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
Jiang, Yaohui
Zheng, Rujie
Sang, Haiqiang
FRONTIERS IN PHARMACOLOGY, 2021, 12
[27] Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction
Docherty, Kieran F.
McMurray, John J. V.
Kalra, Paul R.
Cleland, John G. F.
Lang, Ninian N.
Petrie, Mark C.
Robertson, Michele
Ford, Ian
ESC HEART FAILURE, 2024, 11 (04): : 1875 - 1879
[28] SGLT2 inhibitor therapy in patients with advanced heart failure and reduced ejection fraction
Nuzzi, Vincenzo
Manca, Paolo
Parisi, Francesca
Madaudo, Cristina
Sciacca, Sergio
Cannizzo, Noemi
Mule, Massimiliano
Cipriani, Manlio G.
CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (11)
[29] Atrial Fibrillation Ablation Should Be First-line Therapy in Patients with Heart Failure Reduced Ejection Fraction
Agasthi, Pradyumna
Tseng, Andrew
Lee, Justin Z.
Mulpuru, Siva K.
CARDIOLOGY CLINICS, 2019, 37 (02) : 185 - +
[30] Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
Heath, Rebecca
Johnsen, Hakon
Strain, W. David
Evans, Marc
DIABETES THERAPY, 2022, 13 (02) : 241 - 250

← 1 2 3 4 5 →